FEIBA® (anti-inhibitor coagulant complex)

EviCore covers FEIBA (IV only) for control/prevention of bleeding, perioperative management, and routine prophylaxis in hemophilia A or B patients with inhibitors, and for treatment of bleeding in acquired hemophilia A (compendial); uses not listed (including hemophilia without inhibitors) are excluded. Requests must document the approved indication and clinical purpose, meet policy coverage and safety criteria, follow dosing limits (control/perioperative 50–100 units/kg; prophylaxis 85 units/kg every other day), and are authorized for an initial 3‑month period with 12‑month renewals.

"Control and prevention of bleeding episodes in hemophilia A and B patients with inhibitors (FDA‑approved)"

Sign up to see full coverage criteria, indications, and limitations.